14 févr. 2018 - FDA held a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for Hydexor (proposed tradename), a fixed-dose combination oral tablet, submitted by Charleston Laboratories, Inc., that contains hydrocodone, acetaminophen, and promethazine, for the short- term management of acute pain severe enough to require an opioid analgesic while preventing and reducing opioid-induced nausea
Ajouté au bande de temps:
Date:
14 févr. 2018
Maintenaint
~ Il y a 7 ans et 8 mois